Vivani Medical, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vivani Medical, Inc. is a clinical-stage biopharmaceutical company dedicated to addressing chronic conditions with significant unmet medical needs. Leveraging its proprietary NanoPortal™ platform technology, the company develops a portfolio of miniature, subdermal drug implants designed to deliver sustained, consistent therapeutic levels of medication over extended periods, aiming to enhance patient adherence and tolerability. Its lead programs currently focus on GLP-1 receptor agonists, including semaglutide and exenatide implants, for chronic weight management, obesity, and type 2 diabetes, with the goal of once or twice-yearly administration. Furthermore, through its subsidiary Cortigent, which is in the process of spinning off into an independent entity, Vivani has advanced investigational visual prostheses systems, such as the Orion® system, aiming to restore useful artificial vision for individuals with profound blindness. The company is based in Alameda, California.
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Up 65.0% in March
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update